Trial record 1 of 4 for:    cubist | Exclude Unknown | diarrhea
Previous Study | Return to List | Next Study

Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea

This study has been completed.
Information provided by (Responsible Party):
Cubist Pharmaceuticals Holdings LLC Identifier:
First received: May 10, 2012
Last updated: May 8, 2015
Last verified: May 2015

608 patients with Clostridium Difficile Associated Diarrhea (CDAD) will participate in this study and receive either oral vancomycin or CB-183,315 in a blinded fashion. Treatment will last for 10 days and participants will be followed up for at least 40 days and a maximum of 100 days. The purpose of this study is to evaluate how well CB-183,315 treats CDAD as compared to vancomycin.

Condition Intervention Phase
Clostridium Difficile Infection
Drug: CB-183,315
Drug: oral vancomycin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blinded, Active-Controlled Study of CB-183,315 in Patients With Clostridium Difficile Associated Diarrhea

Resource links provided by NLM:

Further study details as provided by Cubist Pharmaceuticals Holdings LLC:

Primary Outcome Measures:
  • The proportion of subjects with a clinical outcome of cure [ Time Frame: Two days after last dose of study drug ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The clinical response over time based on the length of time it takes for the subjects to fail treatment, recur, die, or become lost to follow-up until Day 40 [ Time Frame: 30 days after the last dose of study drug ] [ Designated as safety issue: No ]
  • The proportion of subjects who sustain a clinical outcome of cure until Day 50 [ Time Frame: 30 days after last dose of study drug ] [ Designated as safety issue: No ]

Enrollment: 608
Study Start Date: May 2012
Study Completion Date: May 2015
Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CB-183,315 250mg/Surotomycin Drug: CB-183,315
250 mg bid for 10 days
Other Name: Surotomycin
Active Comparator: oral vancomycin, 125 mg Drug: oral vancomycin
oral, 125 mg qid for 10 days


Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

To be included in this study, participants must:

  • Sign a consent form;
  • Be older 18 or older and 90 or younger;
  • Have diarrhea, at least 3 times during one day, or 200 mL or liquid stool if using a rectal device;
  • Test positive for Clostridium difficile;
  • If female, must not be pregnant or nursing and take appropriate measures to not get pregnant during the study.

Participants will not be allowed into the study if they:

  • Have toxic megacolon and/or known small bowel ileus;
  • Have received treatment with intravenous immune globulin (IVIG)within the past 30 days;
  • Have received treatment with a fecal transplant within 7 days, and/or if the doctor anticipates to give the participant a fecal transplant during the study;
  • Have received a certain amount of antibacterial therapy specific for current CDAD, unless it is not working;
  • Have received an investigational vaccine against C. difficile;
  • Have received an investigational product containing monoclonal antibodies against toxin A or B within 180 days;
  • Had more than 2 episodes of CDAD within 90 days;
  • Had major gastrointestinal (GI) surgery (i.e. significant bowel resection) within 3 months(this does not include appendectomy or cholecystectomy);
  • Have history of prior inflammatory bowel disease: ulcerative colitis, Crohn's disease, or microscopic colitis;
  • Are unable to discontinue loperamide, diphenoxylate/atropine, or cholestyramine during the duration of the study;
  • Are unable to discontinue opiate treatment unless on a stable dose;
  • Has known positive stool cultures for other enteropathogens including but not limited to Salmonella, Shigella, and Campylobacter;
  • Had stool studies positive for pathogenic ova and/or parasites;
  • Have an intolerance or hypersensitivity to daptomycin and/or vancomycin;
  • Have life-threatening illness at the time of enrollment;
  • Have poor concurrent medical risks that in the opinion of the Investigator the participant should not enroll;
  • Have received an investigational drug or participated in any experimental procedure within 1 month;
  • Have HIV, a CD4 < 200 cells/mm3 within 6 months of start of study therapy;
  • Anticipate that certain antibacterial therapy for a non-CDAD infection will be required for > 7 days;
  • Are unable to discontinue Saccharomyces or similar probiotic;
  • Are on a concurrent intensive induction chemotherapy, radiotherapy, or biologic treatment for active malignancy;
  • Are unable to comply with the protocol requirements;
  • Have any condition that, in the opinion of the Investigator, might interfere;
  • Are not expected to live for less than 8 weeks.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01597505

  Hide Study Locations
United States, Alabama
Birmingham, Alabama, United States
United States, Arizona
Phoenix, Arizona, United States
United States, Arkansas
Little Rock, Arkansas, United States
United States, California
Colton, California, United States
Escondido, California, United States
Long Beach, California, United States
Los Angeles, California, United States
Modesto, California, United States
San Diego, California, United States
United States, Colorado
Lafayette, Colorado, United States
United States, Florida
Aventura, Florida, United States
Clearwater, Florida, United States
Miami, Florida, United States
Naples, Florida, United States
Port Orange, Florida, United States
Tampa, Florida, United States
Zephyrhills, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
Augusta, Georgia, United States
Savannah, Georgia, United States
United States, Illinois
Carbondale, Illinois, United States
Chicago, Illinois, United States
Springfield, Illinois, United States
Urbana, Illinois, United States
United States, Indiana
Indianapolis, Indiana, United States
United States, Kentucky
Louisville, Kentucky, United States
United States, Louisiana
New Orleans, Louisiana, United States
United States, Maryland
Annandale, Maryland, United States
Annapolis, Maryland, United States
Baltimore, Maryland, United States
United States, Massachusetts
Boston, Massachusetts, United States
Brockton, Massachusetts, United States
West Roxbury, Massachusetts, United States
Worcester, Massachusetts, United States
United States, Michigan
Detriot, Michigan, United States
United States, Minnesota
Minneapolis, Minnesota, United States
United States, Missouri
Mexico, Missouri, United States
United States, Montana
Butte, Montana, United States
United States, New Jersey
Hackensack, New Jersey, United States
United States, New York
Bronx, New York, United States
Buffalo, New York, United States
Jamaica Queens, New York, United States
New York, New York, United States
Poughkeepsie, New York, United States
Rochester, New York, United States
Syracuse, New York, United States
United States, North Carolina
Winston Salem, North Carolina, United States
Winston-Salem, North Carolina, United States
United States, North Dakota
Bismark, North Dakota, United States
Fargo, North Dakota, United States
United States, Ohio
Akron, Ohio, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
Mentor, Ohio, United States
Middleburg Heights, Ohio, United States
Toledo, Ohio, United States
United States, Pennsylvania
Philadelphia, Pennsylvania, United States
Sellersville, Pennsylvania, United States
United States, Tennessee
Kingsport, Tennessee, United States
Mountain Home, Tennessee, United States
United States, Texas
Dallas, Texas, United States
San Antonio, Texas, United States
United States, Utah
Salt Lake City, Utah, United States
Feldkirch, Austria
Graz, Austria
Innsbruck, Austria
Salzburg, Austria
St. Poelten, Austria
Vienna, Austria
Bruxelles, Belgium
Charleroi, Belgium
Gent, Belgium
Ghent, Belgium
Kortrijk, Belgium
Canada, Alberta
Edmonton, Alberta, Canada
Canada, British Columbia
Vancouver, British Columbia, Canada
Canada, Manitoba
Winnepeg, Manitoba, Canada
Canada, Ontario
Hamilton, Ontario, Canada
Oshawa, Ontario, Canada
Canada, Quebec
Chicoutimi, Quebec, Canada
Quebec City, Quebec, Canada
St. Jerome, Quebec, Canada
Czech Republic
Brno, Czech Republic
Hradec Kralove, Czech Republic
Kolin, Czech Republic
Kromeriz, Czech Republic
Melnik, Czech Republic
Opava, Czech Republic
Pardubice, Czech Republic
Plzen, Czech Republic
Praha, Czech Republic
Lyon, France
Paris, France
Pringy, France
Rennes, France
Tourcoing, France
Tours, France
Augsburg, Germany
Berlin, Germany
Bochum, Germany
Chorzow, Germany
Heidelberg, Germany
Jena, Germany
Koln, Germany
Leipzig, Germany
Lubeck, Germany
Magdeburg, Germany
Mainz, Germany
Marburg, Germany
Munich, Germany
Potsdam, Germany
Rostock, Germany
Tuebingen, Germany
Ulm, Germany
Weiden i. d. Oberpfalz, Germany
Wurzburg, Germany
Bekescsaba, Hungary
Budapest, Hungary
Debrecen, Hungary
Eger, Hungary
Kaposvar, Hungary
Kistarcsa, Hungary
Miskolc, Hungary
Pecs, Hungary
Szombathely, Hungary
Bnai-Zion, Israel
Ramat Gan, Israel
Tel-Aviv, Israel
Zefat, Israel
Zrifin Beer-Yaakov, Israel
Bagno A Ripole, Italy
Bologna, Italy
Busto Arsizio, Italy
Cremona, Italy
Firenze, Italy
Lecco, Italy
Milano, Italy
Modena, Italy
Pavia, Italy
San Donato Milanese, Italy
Bialystock, Poland
Bialystok, Poland
Bydgoszcz, Poland
Chorzow, Poland
Ciechanow, Poland
Lancut, Poland
Lodz, Poland
Lublin, Poland
Pulawy, Poland
Radom, Poland
Sopot, Poland
Warsaw, Poland
Wroclaw, Poland
Alicante, Spain
Barcelona, Spain
Granada, Spain
Madrid, Spain
Majadahonda, Spain
Mataro, Spain
Reus, Spain
San Sebastian, Spain
Terrassa, Spain
Linkoping, Sweden
Stockholm, Sweden
Uppsala, Sweden
United Kingdom
Blackpool, United Kingdom
Hull, East Yorkshire, United Kingdom
Leicester, United Kingdom
London, United Kingdom
Middlesex, United Kingdom
Norwich, United Kingdom
Sheffield, United Kingdom
Sponsors and Collaborators
Cubist Pharmaceuticals Holdings LLC
Study Director: Ming Yu, MD, PhD Cubist Pharmaceuticals Sr. Clinical Research Scientist
  More Information

No publications provided

Responsible Party: Cubist Pharmaceuticals Holdings LLC Identifier: NCT01597505     History of Changes
Other Study ID Numbers: LCD-CDAD-10-07
Study First Received: May 10, 2012
Last Updated: May 8, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Cubist Pharmaceuticals Holdings LLC:
Clostridium difficile Associated Diarrhea
Clostridium difficile Infection

Additional relevant MeSH terms:
Signs and Symptoms
Signs and Symptoms, Digestive
Anti-Bacterial Agents
Anti-Infective Agents
Pharmacologic Actions
Therapeutic Uses processed this record on October 02, 2015